Skip to main content

SGLT-2 Inhibitor Use and Incidence of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus

    Basic Details
    Date Posted
    Status
    Complete
    Medical Product
    canagliflozin
    dapagliflozin
    empagliflozin
    sitagliptin
    sodium-glucose cotransporter-2 (SGLT-2) inhibitor
    Health Outcome(s)
    diabetic ketoacidosis
    Description

    The goal of this request was to estimate rates of diabetic ketoacidosis (DKA) among new users of sodium-glucose cotransporter-2 (SGLT-2) inhibitors canagliflozin, dapagliflozin, empagliflozin, or sitagliptin in the Sentinel Distributed Database (SDD). Data from March 1, 2013 through June 30, 2018 from 17 Data Partners contributing to the SDD were included in this report. This request was distributed to Data Partners on November 28, 2018.